The Comparative analysis of different Brands of “AMLODIPINE”

*D. Meghashyam, P. Hari, B. Anant
M.S. Ramaiah College of Pharmacy - [Msrcp], Bangalore

Correspondence Author:
Accepted 2018-09-17, Published 2018-10-25

Abstract:
This project was undertaken to know the market potential of different brands of Amlodipine which are already existing in the market. It starts with the brief introduction of Indian Pharmaceutical Industry. By having a look at Chapter two of the project i.e. Introduction, one can know about the Indian pharmaceutical industry, from this part one can know about key players in this field, about the growth of pharmaceutical industry, problems of the industry. A further look at the chapter three i.e. Drug description, one can know about the drug, drugs action, their benefits, their side effects, etc. In the chapter four i.e. Disease Description one can know about the disease, from this chapter one can easily be familiar how harmful is the disease, causes of the disease, prevention of the disease, etc. In the Research Methodology, the objectives of the study have been described along with the steps followed to attain the objectives. In carrying out the course of the research study, a survey on 70 Doctors and 100 Chemists shops was undertaken in Moradabad. Going through the Chapter six of the project i.e. Findings and Analysis, the data collected has been presented and analyzed to meet the objectives of the study.

Key Words: Amlodipine, Drug, Disease

Introduction:
Amlodipine Besylates is the besylate salt of amlodipine, a long-acting calcium channel blocker. Amlodipine besylate is chemically described as 3-Ethyl-5-methyl (±)-2 [(2-aminoethoxy) methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate, monobenzenesulphonate. Its empirical formula is C20H25CIN2O5•C6H6O3S, and its structural formula is: Amlodipine besylate is a white crystalline powder with a molecular weight of 567.1. It is slightly soluble in water and sparingly soluble in ethanol. Amlodipine (amlodipin besylate) tablets are formulated as white tablets equivalent to 2.5, 5 and 10 mg of amlodipine for oral administration. In addition to the active ingredient, amlodipine besylate, each tablet contains the following inactive ingredients: microcrystalline cellulose, dibasic calcium phosphate anhydrous, sodium starch glycolate, and magnesium stearate.

Indication:
Hypertension Amlodipine is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.

Coronary Artery Disease (CAD):

Chronic Stable Angina: Amlodipine is indicated for the symptomatic treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal agents.

Vasospastic Angina (Prinzmetal's or Variant Angina): Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal drugs. Angiographically Documented CAD In patients with recently documented CAD by angiography and without heart failure or an ejection fraction <40%, Amlodipine is indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure.

Dosage and Administration:
Adults: The usual initial antihypertensive oral dose of Amlodipine is 5 mg once daily with a maximum dose of 10 mg once daily. Small, fragile, or elderly individuals, or patients with hepatic insufficiency may be started on 2.5 mg once daily and this dose may be used when adding Amlodipine to other antihypertensive therapy. Dosage should be adjusted according to each patient's need. In general,
titration should proceed over 7 to 14 days so that the physician can fully assess the patient's response to each dose level. Titration may proceed more rapidly, however, if clinically warranted, provided the patient is assessed frequently. The recommended dose for chronic stable or vasospastic angina is 5-10 mg, with the lower dose suggested in the elderly and in patients with hepatic insufficiency. Most patients will require 10 mg for adequate effect. The recommended dose range for patients with coronary artery disease is 5-10 mg once daily. In clinical studies the majority of patients required 10 mg.

**Children:** The effective antihypertensive oral dose in pediatric patients ages 6-17 years is 2.5 mg to 5 mg once daily. Doses in excess of 5 mg daily have not been studied in pediatric patients. Co-administration with Another Antihypertensive and/or Antianginal.

**Drugs:**
Amlodipine has been safely administered with thiazides, ACE inhibitors, beta-blockers, long-acting nitrates, and/or sublingual nitroglycerin.

**Side Effects:**
The following events occurred in <1% but >0.1% of patients in controlled clinical trials or under conditions of open trials or marketing experience where a causal relationship is uncertain; they are listed to alert the physician to a possible relationship:

- **Cardiovascular:** arrhythmia (including ventricular tachycardia and atrial fibrillation), bradycardia, chest pain, hypotension, peripheral ischemia, syncope, tachycardia, postural dizziness, postural hypotension, vasculitis.

- **Central and Peripheral Nervous System:** hypoesthesia, neuropathy peripheral, paresthesia, tremor, vertigo.

- **Gastrointestinal:** anorexia, constipation, dyspepsia, dysphagia, diarrhea, flatulence, pancreatitis, vomiting, gingival hyperplasia.

- **General:** allergic reaction, asthenia, back pain, hot flushes, malaise, pain, rigors, weight gain, weight decrease.

- **Musculoskeletal System:** arthralgia, arthritis, muscle cramps, myalgia.

- **Psychiatric:** sexual dysfunction (male** and female), insomnia, nervousness, depression, abnormal dreams, anxiety, depersonalization.

- **Respiratory System:** dyspnea, epistaxis.

- **Skin and Appendages:** angioedema, erythema multiforme, pruritus, rash, rash erythematous, rash maculopapular.

- **Special Senses:** abnormal vision, conjunctivitis, diplopia, eye pain, tinnitus.

- **Urinary System:** micturition frequency, micturition disorder, nocturia.

- **Autonomic Nervous System:** dry mouth, sweating increased.

- **Metabolic and Nutritional:** hyperglycemia, thirst.

- **Hemopoietic:** leukopenia, purpura, thrombocytopenia.

**Drug Interaction:**
In vitro data indicate that Amlodipine has no effect on the human plasma protein binding of digoxin, phenytoin, warfarin, and indomethacin.

**Effect of other agents on Amlodipine:**
- **Cimetidine:** Co-administration of Amlodipine with cimetidine did not alter the pharmacokinetics of Amlodipine.

- **Grapefruit Juice:** Co-administration of 240 mL of grapefruit juice with a single oral dose of amlodipine 10 mg in 20 healthy volunteers had no significant effect on the pharmacokinetics of amlodipine.

- **Maalox (Antacid):** Co-administration of the antacid Maalox with a single dose of Amlodipine had no significant effect on the pharmacokinetics of Amlodipine.

- **Sildenafil:** A single 100 mg dose of sildenafil (Viagra®) in subjects with essential hypertension had no effect on the pharmacokinetic parameters of Amlodipine. When Amlodipine and sildenafil were used in combination, each agent independently exerted its own blood pressure lowering effect.

**Effect of Amlodipine on other agents:**
- **Atorvastatin:** Co-administration of multiple 10 mg doses of Amlodipine with 80 mg of atorvastatin resulted in no significant change in the steady state pharmacokinetic parameters of atorvastatin.

- **Digoxin:** Co-administration of Amlodipine with digoxin did not change serum digoxin levels or digoxin renal clearance in normal volunteers.

- **Ethanol (Alcohol):** Single and multiple 10 mg doses of Amlodipine had no significant effect on the pharmacokinetics of ethanol.
Warfarin: Co-administration of Amlodipine with warfarin did not change the warfarin prothrombin response time. In clinical trials, Amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs.

Precautions:

General: Since the vasodilation induced by Amlodipine is gradual in onset, acute hypotension has rarely been reported after oral administration. Nonetheless, caution as with any other peripheral vasodilator, should be exercised when administering Amlodipine, particularly in patients with severe aortic stenosis. Use in Patients with Congestive Heart Failure In general, calcium channel blockers should be used with caution in patients with heart failure.

Beta-Blocker Withdrawal: Amlodipine is not a beta-blocker and therefore gives no protection against the dangers of abrupt beta-blocker withdrawal; any such withdrawal should be by gradual reduction of the dose of beta-blocker.

Patients with Hepatic Failure Since: Amlodipine is extensively metabolized by the liver and the plasma elimination half-life (t 1/2) is 56 hours in patients with impaired hepatic function, caution should be exercised when administering Amlodipine to patients with severe hepatic impairment.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Rats and mice treated with amlodipine maleate in the diet for up to two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5 amlodipine mg/kg/day showed no evidence of carcinogenic effect of the drug. For the mouse, the highest dose was, on a mg/m² basis, similar to the maximum recommended human dose of 10 mg amlodipine/day*. For the rat, the highest dose, was on a mg/m² basis, about twice the maximum recommended human dose*. Mutagenicity studies conducted with amlodipine maleate revealed no drug related effects at either the gene or chromosome level. There was no effect on the fertility of rats treated orally with amlodipine maleate (males for 64 days and females for 14 days prior to mating) at doses up to 10 mg amlodipine/kg/day (8 times* the maximum recommended human dose of 10 mg/day on a mg/m² basis).

Pregnancy Category C: No evidence of teratogenicity or other embryo/fetal toxicity was found when pregnant rats and rabbits were treated orally with amlodipine maleate at doses up to 10 mg amlodipine/kg/day (respectively 8 times* and 23 times* the maximum recommended human dose of 10 mg on a mg/m² basis) during their respective periods of major organogenesis. However, litter size was significantly decreased (by about 50%) and the number of intrauterine deaths was significantly increased (about 5-fold) in rats receiving amlodipine maleate at a dose equivalent to 10 mg amlodipine/kg/day for 14 days before mating and throughout mating and gestation. Amlodipine maleate has been shown to prolong both the gestation period and the duration of labor in rats at this dose.

There are no adequate and well-controlled studies in pregnant women. Amlodipine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers: It is not known whether amlodipine is excreted in human milk. In the absence of this information, it is recommended that nursing be discontinued while Amlodipine is administered.

Pediatric Use: The effect Amlodipine on blood pressure in patients less than 6 years of age is not known.

Overdose:

Single oral doses of amlodipine maleate equivalent to 40mg amlodipine/kg and 100mg amlodipine/kg in mice and rats, respectively, caused deaths. Single oral amlodipine maleate doses equivalent to 4 or more mg amlodipine/kg or higher in dogs (11 or more times the maximum recommended human dose on a mg/m² basis) caused a marked peripheral vasodilation and hypotension. Overdosage might be expected to cause excessive peripheral vasodilation with marked hypotension and possibly a reflex tachycardia. In humans, experience with intentional overdosage of Amlodipine is limited. Reports of intentional overdosage include a patient who ingested 250 mg and was asymptomatic and was not hospitalized; another (120 mg) was hospitalized, underwent gastric lavage and remained normotensive; the third (105 mg) was hospitalized and had hypotension (90/50 mmHg) which normalized following plasma expansion. A case of accidental drug overdose has been documented in a 19-month-old male who ingested 30 mg amlodipine (about 2 mg/kg). During the emergency room presentation, vital signs were stable with no evidence of hypotension, but a heart rate of 180 bpm. Ipecac was administered 3.5 hours after ingestion and on subsequent observation

(overnight) no sequelae were noted. If massive overdose should occur, active cardiac and respiratory monitoring should be instituted. Frequent blood pressure measurements are essential. Should hypotension occur, cardiovascular support including elevation of the extremities and the judicious administration of fluids should be initiated. If hypotension remains unresponsive to these conservative measures, administration of vasopressors (such as phenylephrine) should be considered with attention to circulating volume and urine output. Intravenous calcium gluconate may help to reverse the effects of calcium entry blockade. As Amlodipine is highly protein bound, hemodialysis is not likely to be of benefit.

Clinical Pharmacology:

Mechanism of Action: Amlodipine is a dihydropyridine calcium antagonist (calcium ion antagonist or slow-channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that amlodipine binds to both dihydropyridine and nondihydropyridine binding sites.

The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels.

Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells. Negative inotropic effects can be detected in vitro but such effects have not been seen in intact animals at therapeutic doses. Serum calcium concentration is not affected by amlodipine. Within the physiologic pH range, amlodipine is an ionized compound (pKa=8.6), and its kinetic interaction with the calcium channel receptor is characterized by a gradual rate of association and dissociation with the receptor binding site, resulting in a gradual onset of effect. Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure. The precise mechanisms by which amlodipine relieves angina have not been fully delineated, but are thought to include the following:

Exertional Angina: In patients with exertional angina, Amlodipine reduces the total peripheral resistance (afterload) against which the heart works and reduces the rate pressure product, and thus myocardial oxygen demand, at any given level of exercise.

Vasospastic Angina: Amlodipine has been demonstrated to block constriction and restore blood flow in coronary arteries and arterioles in response to calcium, potassium epinephrine, serotonin, and thromboxane A2 analog in experimental animal models and in human coronary vessels in vitro. This inhibition of coronary spasm is responsible for the effectiveness of Amlodipine in vasospastic (Prinzmetal's or variant) angina.

Pharmacokinetics and Metabolism:

After oral administration of therapeutic doses of Amlodipine, absorption produces peak plasma concentrations between 6 and 12 hours. Absolute bioavailability has been estimated to be between 64 and 90%. The bioavailability of Amlodipine is not altered by the presence of food. Amlodipine is extensively (about 90%) converted to inactive metabolites via hepatic metabolism with 10% of the parent compound and 60% of the metabolites excreted in the urine. Ex vivo studies have shown that approximately 93% of the circulating drug is bound to plasma proteins in hypertensive patients. Elimination from the plasma is biphasic with a terminal elimination half-life of about 30-50 hours. Steady-state plasma levels of amlodipine are reached after 7 to 8 days of consecutive daily dosing. The pharmacokinetics of amlodipine are not significantly influenced by renal impairment. Patients with renal failure may therefore receive the usual initial dose. Elderly patients and patients with hepatic insufficiency have decreased clearance of amlodipine with a resulting increase in AUC of approximately 40-60%, and a lower initial dose may be required. A similar increase in AUC was observed in patients with moderate to severe heart failure. Pediatric Patients Sixty-two hypertensive patients aged 6 to 17 years received doses of Amlodipine between 1.25 mg and 20 mg. Weight-adjusted clearance and volume of distribution were similar to values in adults.

Pharmacodynamic:

Hemodynamics: Following administration of therapeutic doses to patients with hypertension, Amlodipine produces vasodilation resulting in a reduction of supine and standing blood pressures. These decreases in blood pressure are not accompanied by a significant change in heart rate or plasma catecholamine levels with chronic dosing. Although the acute intravenous administration of amlodipine decreases arterial blood pressure and increases heart rate in hemodynamic studies of patients with chronic stable angina, chronic oral
administration of amlopidine in clinical trials did not lead to clinically significant changes in heart rate or blood pressures in normotensive patients with angina. With chronic once daily oral administration, antihypertensive effectiveness is maintained for at least 24 hours. Plasma concentrations correlate with effect in both young and elderly patients. The magnitude of reduction in blood pressure with Amlodipine is also correlated with the height of pretreatment elevation; thus, individuals with moderate hypertension (diastolic pressure 105-114 mmHg) had about a 50% greater response than patients with mild hypertension (diastolic pressure 90-104 mmHg). Normotensive subjects experienced no clinically significant change in blood pressures (+1/-2 mmHg). In hypertensive patients with normal renal function, therapeutic doses of Amlodipine resulted in a decrease in renal vascular resistance and an increase in glomerular filtration rate and effective renal plasma flow without change in filtration fraction or proteinuria. As with other calcium channel blockers, hemodynamic measurements of cardiac function at rest and during exercise (or pacing) in patients with normal ventricular function treated with Amlodipine have generally demonstrated a small increase in cardiac index without significant influence on dP/dt or on left ventricular end diastolic pressure or volume. In hemodynamic studies, Amlodipine has not been associated with a negative inotropic effect when administered in the therapeutic dose range to intact animals and man, even when co-administered with betablockers to man. Similar findings, however, have been observed in normals or well-compensated patients with heart failure with agents possessing significant negative inotropic effects.

**Electrophysiologic Effects:** Amlodipine does not change sinoatrial nodal function or atrioventricular conduction in intact animals or man. In patients with chronic stable angina, intravenous administration of 10 mg did not significantly alter A-H and H-V conduction and sinus node recovery time after pacing. Similar results were obtained in patients receiving Amlodipine and concomitant beta blockers. In clinical studies in which Amlodipine was administered in combination with beta-blockers to patients with either hypertension or angina, no adverse effects on electrocardiographic parameters were observed. In clinical trials with angina patients alone, Amlodipine therapy did not alter electrocardiographic intervals or produce higher degrees of AV blocks.

**Conclusions:**

From the analysis of the collected data following conclusions can be drawn.

1. Calchek: The market share of this product in Moradabad is just 8.98% least among all other drugs of the same segment. The reason accounting for this are less awareness on the part of the chemists and the doctors and the inefficiency of the distribution channel and the medical representative to keep them update with all the new launches. At the time of study this product was not available at most of the retail counter.

2. Amtas: The movement of this product is also less with market share of just 9.72 % of the total market share. The reason being the lack of follow-up campaign and positioning by the company.

3. Amlogard: The sales of this product are satisfactory in terms of high stocks kept by the chemists and prescribe by doctors. The market share of this product is 14.11 %.

4. Amlopre: This product is the market leader in this segment with market share of 16.21 % of the total market share. The reason of the high movement is follow-up campaign, sales promotion and higher frequency of visit of medical representative to the Doctor.

5. Amlosyl: The sales of this product good in comparison to other it second market leader after Amlopre with market share of 15.06 %. The reason is higher sales promotion by the company its effectiveness and price.

6. Amlokin: Its market share is 14.70 %, almost similar to Methergine. This product account third rank among these product on the basis of market share and movement of the product.

7. Amlosun: This product also accounts average market share in comparison to other products with 12.19 % of the total market share. Though it is moving at a higher rate in comparison to Amtas and Amlocor and this product were available at most of the counter during the study.

8. Amlocor:. Its market share is 9.03 % of the total market share. The reason of this less movement is again the less awareness among the retailers.

**References:**

1) Sharma, R.S., Urban decay of India c.A.D.300- C.AD 1000, Delhi, 1987,134-77
2) Sharma, R.S., Indian Feudalism, Madras, Macmillan, 1980, 102-05
4) Singh, Upinder., A History of Ancient and Early Medieval India: from the stone age to the twelfth century AD, New Delhi, Pearson Education, 2008, 585
5) Singh, Upinder., A History of Ancient and Early Medieval India: from the stone age to the twelfth century AD, 585
6) Chaudhuri, K.N., Trade and Civilization in the Indian Ocean; An economic History from the rise of Islam to 1750, 1985, New Delhi, Munshiram Manoharlal, 37-41.
8) Jain, V. K., Trade and Traders in Western India, New Delhi, Munshiram Manoharlal, 1990
9) Singh, Upinder., A History of Ancient and Early Medieval India: from the stone age to the twelfth century AD, 586
10) Singh, Upinder., A History of Ancient and Early Medieval India: from the stone age to the twelfth century AD, 587
12) Liu, 1996, Silk and Religion: An exploration of material life and the thought of people AD 600-1200, Delhi, Oxford University Press, 49-72
13) Singh, Upinder., A History of Ancient and Early Medieval India: from the stone age to the twelfth century AD, 587
14) Abraham, Meera., Two Medieval merchant guilds of South India. New Delhi, Manohar, 1988